• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Are There any Minor Risks Involved with the ‘Opportunistic’ Removal of Fallopian Tubes to Prevent Cancer During Hysterectomy or Sterilization Procedures

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • High-grade serous ovarian cancer appears to actually begin in the fallopian tube
  • Professional colleges (including ACOG and SOGC) are recommending ‘opportunistic salpingectomy’ for cancer prevention in average risk population
    • At time of hysterectomy (ovarian preservation)
    • As a mode of permanent sterilization
  • Data is limited regarding whether there are minor, clinically significant complications associated with opportunistic salpingectomy
  • Hanley et al. (AJOG, 2018) sought to address the risks of minor complications associated with opportunistic salpingectomy

METHODS:

  • Population-based retrospective cohort study (2008-2014) in British Columbia
  • Participants: Women had either
    • Opportunistic salpingectomy with hysterectomy
    • Hysterectomy alone
    • Hysterectomy with a bilateral salpingo-oophorectomy (BSO)
    • Opportunistic salpingectomy for sterilization
    • Tubal ligation (tubes left in situ)
  • Excluded surgeries for gyn malignancies
  • Adjusted odds ratio (aOR): Odds ratios adjusted for
    • Other gynecologic conditions | Surgical approach | Patient age
  • Primary outcomes: The following occurrences within 2 weeks after discharge
    • Surgical infection | Surgical complication | Orders for lab tests and imaging | Frequency of filled prescription for an antibiotic or prescription strength analgesic (exluding over the counter pain relievers)

RESULTS:

  • 49,275 women were included in the study
    • Hysterectomy alone: 8231
    • Hysterectomy with opportunistic salpingectomy: 8508
    • Hysterectomy with BSO: 7273
    • Tubal ligation: 19,424
    • Opportunistic salpingectomy for sterilization: 5839
  • Women who underwent opportunistic salpingectomy had
    • No increased risk for physician visits for surgical infection, surgical complication, additional lab or imaging orders
    • No increased risk for additional antibiotic prescriptions
  • Women who underwent opportunistic salpingectomy had a 20% increased odds of filling a prescription for an analgesic within 2 weeks postop
    • Hysterectomy with opportunistic salpingectomy: aOR 1.23; 95%CI, 1.15-1.32
    • Opportunistic salpingectomy for sterilization: aOR 1.21; 95%CI, 1.14-1.29
    • This finding was no longer present at 1 month

CONCLUSION:

  • There is no risk for minor complications with the addition of opportunistic salpingectomy when compared to hysterectomy alone or tubal ligation
  • There was a slight increase in risk for additional prescriptions for analgesics, however, the authors state that “this risk will likely be far outweighed by the potential long-term benefit”

Learn More – Primary Sources:

Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: A cohort study from British Columbia, Canada

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

‘Opportunistic’ Salpingectomy at the Time of Hysterectomy: Risks vs Benefits
Should Fallopian Tubes Also Be Removed During Ovarian Conserving Benign Hysterectomy? 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site